Wall Street Zen Upgrades Haemonetics (NYSE:HAE) to “Buy”

Haemonetics (NYSE:HAE) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday.

Several other equities research analysts also recently weighed in on the company. Raymond James Financial reaffirmed an “outperform” rating and issued a $90.00 target price on shares of Haemonetics in a research report on Friday, November 14th. Needham & Company LLC upped their price target on Haemonetics from $68.00 to $78.00 and gave the stock a “buy” rating in a report on Friday, November 7th. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $62.00 price objective (down previously from $85.00) on shares of Haemonetics in a research note on Friday, August 8th. Weiss Ratings reissued a “hold (c-)” rating on shares of Haemonetics in a research report on Monday. Finally, BTIG Research reaffirmed a “buy” rating and set a $88.00 price target on shares of Haemonetics in a report on Friday, November 21st. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $79.70.

Haemonetics Trading Up 0.2%

Shares of HAE stock opened at $83.98 on Friday. The stock has a market cap of $3.93 billion, a price-to-earnings ratio of 24.56, a price-to-earnings-growth ratio of 1.51 and a beta of 0.30. The company has a quick ratio of 1.03, a current ratio of 1.64 and a debt-to-equity ratio of 1.08. Haemonetics has a fifty-two week low of $47.31 and a fifty-two week high of $85.23. The firm’s 50 day moving average price is $61.83 and its two-hundred day moving average price is $63.84.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.12 by $0.15. Haemonetics had a net margin of 12.67% and a return on equity of 27.22%. The company had revenue of $327.32 million during the quarter, compared to analyst estimates of $311.61 million. During the same quarter in the prior year, the business earned $1.12 earnings per share. The business’s quarterly revenue was down 5.3% compared to the same quarter last year. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. On average, analysts anticipate that Haemonetics will post 4.55 EPS for the current year.

Institutional Investors Weigh In On Haemonetics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. EverSource Wealth Advisors LLC lifted its position in shares of Haemonetics by 2,640.0% during the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock worth $31,000 after purchasing an additional 396 shares during the last quarter. GAMMA Investing LLC lifted its holdings in Haemonetics by 59.4% during the 2nd quarter. GAMMA Investing LLC now owns 443 shares of the medical instruments supplier’s stock worth $33,000 after buying an additional 165 shares during the last quarter. Quarry LP grew its position in shares of Haemonetics by 63.4% in the 1st quarter. Quarry LP now owns 495 shares of the medical instruments supplier’s stock worth $31,000 after acquiring an additional 192 shares in the last quarter. UMB Bank n.a. increased its holdings in shares of Haemonetics by 91.7% in the 2nd quarter. UMB Bank n.a. now owns 669 shares of the medical instruments supplier’s stock valued at $50,000 after acquiring an additional 320 shares during the last quarter. Finally, Versant Capital Management Inc increased its holdings in shares of Haemonetics by 216.4% in the 3rd quarter. Versant Capital Management Inc now owns 829 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 567 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.